Your doctor prescribed Entyvio because it's the right choice for you. But then your insurer denied it.

That’s frustrating on its own, but it’s especially galling for Entyvio. The very reason gastroenterologists often choose Entyvio (your IBD needs a biologic that works in the gut without suppressing your entire immune system) is also exactly what most insurer step therapy policies ignore when they demand you try a TNF blocker first. Though there are other reasons Entyvio may be denied, this one is all too common.

Entyvio (vedolizumab) has been FDA-approved since 2014 for moderate-to-severe ulcerative colitis and Crohn’s disease. Unlike TNF inhibitors and JAK inhibitors, it targets α4β7 integrin specifically in the GI tract rather than suppressing immunity systemically.

That mechanism makes it the preferred biologic for patients with infection risks, a history of malignancy, or complications from broader immunosuppression. It’s also one of the most expensive biologics on the market (roughly $9,900 per IV infusion, approximately $3,500 per subcutaneous dose), with no biosimilar currently available. Insurers deny it often.

But denials can be overturned. Fewer than 1% of denied claims are ever appealed, according to KFF’s analysis of federal marketplace data. When patients do challenge with proper evidence, the results look very different. We see this daily at Claimable, where our appeals succeed over 80% of the time in established conditions.

Entyvio denials follow their own patterns. A UC patient denied because the insurer demands TNF failure is in a different fight than a Crohn’s patient denied during the transition from IV to subcutaneous maintenance, or one whose insurer pulled Entyvio from the formulary entirely. This guide covers each type and how to respond.

Why Insurance Companies Deny Entyvio Coverage

The specific reason on your denial letter determines what evidence you need, which arguments will work, what type of appeal you should submit. A generic appeal that ignores your actual denial type is unlikely to succeed, and most plans cap the number of appeals you can file.

Why Entyvio Denials Are Their Own Category

Entyvio’s gut-selective mechanism is the reason doctors prescribe it, but it’s also the reason insurers resist covering it. Most insurers still require TNF failure before they’ll approve it, forcing patients through systemically immunosuppressive drugs before granting the one designed to avoid those risks.

It comes in two formulations on two different insurance benefits. Entyvio IV is billed under the medical benefit, Entyvio SC under the pharmacy benefit. Patients who complete IV induction and transition to SC maintenance need a separate PA on the pharmacy side, creating two potential denial points for the same drug.

There is no biosimilar available yet. The first vedolizumab biosimilar application was accepted by the FDA in June 2026 (Alvotech’s AVT16, an IV-only product), with an FDA decision expected in early 2027. But Takeda’s patent runs until May 2032, so a biosimilar isn’t expected to reach patients for years.

And vedolizumab has a slower onset than some competing biologics (6-14 weeks for full response), which means some insurers pull coverage before the drug has had enough time to work.

What We See In Entyvio Appeals

Denial letters are designed to close the conversation. They shouldn’t. Here are the most common Entyvio denial types, what they actually mean, and where to focus first:
‍

Step Therapy and TNF Failure Required

This is the most common Entyvio denial. Most plans require documented failure on at least one TNF blocker before they’ll cover vedolizumab. Some require failure on two, or require an immunomodulator trial on top of TNF failure.

The argument that wins: The 2025 ACG Crohn’s disease guideline recommends vedolizumab among the advanced therapies for moderate-to-severe Crohn’s without mandating TNF failure as a prerequisite, and the 2025 ACG ulcerative colitis guideline likewise recommends vedolizumab for induction in moderate-to-severe UC. The AGA guidelines recommend vedolizumab for induction and maintenance as well. If your doctor chose vedolizumab because of a contraindication to TNF blockers (active TB, prior lymphoma, demyelinating disease, heart failure, recurrent serious infections), that is a documented medical reason, and most state step therapy exception laws are designed to cover exactly this scenario.

Not Medically Necessary

This denial is common. Sometimes it reflects a request that didn't spell out the clinical picture; other times a reviewer applied the plan's own criteria and decided your case didn't clearly meet them. Your appeal is where you make the full case either way.

What a strong resubmission includes: diagnosis with current ICD-10 codes, disease severity documented with objective measures (partial Mayo score or full Mayo score for UC, CDAI or Harvey-Bradshaw Index for Crohn’s, plus endoscopy findings if available). Include complete treatment history with dates, durations, doses, and specific reasons each prior therapy was stopped. Add a clinical rationale for why vedolizumab is the appropriate next treatment.

IV-to-SC Transition Denied

When a patient completes IV induction and their gastroenterologist prescribes the SC pen for maintenance, a new PA is required on the pharmacy side. That PA can be denied even though the patient is already approved for the same medication on the medical side.

The fix: submit the SC PA with documentation of successful IV induction and current clinical response. Frame it as continuation of established therapy, not initiation of a new treatment. If the pharmacy benefit denies it, your doctor can request that maintenance continue via IV infusion while the SC denial is appealed.

Continuation Denied

Vedolizumab’s onset of action can take 6 to 14 weeks (longer for Crohn’s). Some insurers build early response checkpoints into their criteria and pull coverage before the drug has had enough time to work.

When to push back: if you’re within the expected response window and showing any trajectory of improvement (labs trending down, symptoms improving, reduced steroid use), document that trajectory and have your gastroenterologist state that the response pattern is consistent with vedolizumab’s mechanism. The insurer’s timeline should match the drug’s pharmacology.

Formulary Exclusion

Some plans have begun removing Entyvio IV from their formularies. Document your clinical stability on vedolizumab, why alternatives are inappropriate (prior TNF failures, contraindications to JAK inhibitors), and the risk of switching a responding IBD patient to a different biologic. If your state has non-medical switching protections, reference them directly.

Site of Care Restriction

If your insurer objects to where you receive your infusion rather than whether you need it, your doctor can submit a site-of-care exception if the alternative facility can’t safely accommodate your needs. If the alternative is clinically appropriate, transitioning is often the fastest path to continued coverage.

How to Appeal an Entyvio Denial (Step by Step)

Step 1: Find Your Deadline

Your denial letter must include the reason for denial, your appeal rights, and the filing deadline. Most commercial plans allow 180 days, but UnitedHealthcare limits many plans to 65 calendar days and Medicare plans follow CMS timelines. Missing the deadline eliminates your rights regardless of how strong your case is.

Step 2: Talk to Your Doctor

Both you and your doctor have the ability to appeal. Your doctor's appeal typically focuses on the clinical appeal (resubmitting the PA, writing a letter of medical necessity, requesting peer-to-peer review). You can file your own patient-initiated appeal, and can also include personal impact, policy precedent, and legal arguments. Patient appeals work on faster timelines and include more legal rights than a provider's appeal, so if your doctor can't or won't appeal, or if their appeal gets denied, a patient appeal is a great option.

Step 3: Verify Your Documentation

Confirm that your ICD-10 codes, disease severity scores, and treatment history are complete and current, following the documentation requirements for your denial type above. For IV-to-SC denials, document successful IV induction. For continuation denials, document trending improvements.

Step 4: Get a Letter of Medical Necessity

While appeals can be approved without a LOMN, it can be helpful – ask your doctor to write you one. A strong LOMN includes your diagnosis with severity scores, complete treatment history, and clinical rationale for vedolizumab addressing the insurer’s specific denial reason. Also include any denial-specific documentation, such as TNF contraindications for step therapy denials, clinical trajectory for continuation denials, or successful IV induction for transition denials.

Step 5: Build the Appeal Package

A complete appeal includes the cover letter, the LOMN, supporting clinical records, and your personal statement. The winning structure:

Start with your story, covering the real-world impact of IBD on your daily life.

Follow with clinical evidence from the ACG 2025 and AGA guidelines supporting vedolizumab for your condition.

Close with policy and legal analysis showing how your case meets the plan’s own criteria, plus ACA protections and any applicable state step therapy exception laws.

Step 6: Submit and Track

Submit per the denial letter instructions. Insurers must respond within 30 days (standard) or 72 hours (urgent). Keep records of everything: fax confirmations, certified mail receipts, representative names.

Step 7: Escalate If Denied Again

You have the right to external review by an independent third party. Their decisions are binding on the insurer in most states. Additional options include state Department of Insurance complaints, ERISA remedies, and state step therapy exception laws.

Appeal Timelines: How Long Does an Entyvio Appeal Take?

The biggest factor in speed is submitting a complete package from the start. An appeal that arrives with the letter of medical necessity, clinical documentation, and personal statement can help your appeal move quicker. The average Claimable appeal gets a response in just 10 days.

FAQs

Why was my Entyvio denied when my doctor specifically chose it for safety reasons?

Most insurer step therapy policies don’t account for the clinical reasoning behind a prescriber’s drug selection. They require TNF blocker failure before vedolizumab regardless of why your doctor chose it. If the reason was a safety concern with systemic immunosuppression, that’s a step therapy exception argument, and a strong one. But you have to make it explicitly in the appeal with documentation.

Can I appeal an Entyvio denial myself?

Yes. Patient appeals run on a separate legal track from your gastroenterologist’s clinical appeal, with guaranteed response timelines, the right to external review, and multiple levels of internal appeal.

Is there a biosimilar or generic version of Entyvio?

Not yet. The first vedolizumab biosimilar application was accepted by the FDA in June 2026, with an FDA decision expected in early 2027. But Takeda’s patent runs until May 2032, so a biosimilar isn’t expected to reach patients for years.

How much does Entyvio cost without insurance?

Entyvio IV runs roughly $9,900 per infusion. The SC pen costs approximately $3,500 per dose. Takeda offers financial support through EntyvioConnect, including a copay card for commercially insured patients and a patient assistance program for eligible uninsured patients.

Claimable’s physician-led team has helped patients recover over $30 million in care access by fighting insurance denials. We’re SOC 2 Type II certified and HIPAA compliant. Learn more about how Claimable works →